It may be possible to design drugs that mimic the positive health benefits of gut bacteria to treat diseases such as type II diabetes, a new study has found.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.